Index

A

acetylcysteine, 166
aciclovir, 114, 116, 117
acquired immunodeficiency syndrome (AIDS), 153
Actinomyces israelii conjunctivitis, 112
acute conjunctivitis, 109–110
  clinical features, 111
  hemorrhagic, 118–119
  see also bacterial conjunctivitis; neonatal conjunctivitis; viral conjunctivitis
adenovirus, 55, 111, 115, 153
  adenoviral keratoconjunctivitis, 115–116
    causes, 115
    differential diagnosis, 115, 126
    epidemiology, 115
    laboratory investigations, 115
    therapy, 115–116
adhesins, 28
adhesion complexes, 5, 18
adhesion molecules, 18–20, 27–28
Alcian blue stain, 12
allergen challenge, 58, 138
allergic conjunctivitis, 42–43, 52–66
  atopic keratoconjunctivitis, 42, 53, 55–56, 65–66, 106
  contact conjunctivitis, 58
  giant papillary conjunctivitis (GPC), 48, 53, 54, 56–58, 66
  hay fever conjunctivitis, 42, 53, 63–64
  laboratory investigations, 58–59
    conjunctival allergen challenge, 58
    conjunctival impression cytology, 58–59
    IgE in tears, 58
    skin tests, 58
  perennial conjunctivitis, 53–54, 63–64
  therapy, 59–66
    drug therapy, 59–63
    environmental control, 59
    immunotherapy, 63–66
    symptomatic measures, 59
  vernal conjunctivitis, 33, 42, 48, 53, 54–55, 57, 64–65, 127
allergy, 31, 34–35, 40, 42–43, 52, 57, 156
  environmental control, 59
  ocular, 106
  see also allergic conjunctivitis; iatrogenic disorders
alpha-chymotrypsin, 171
amylosis, 150, 156
anaphylactic reactions, 34
anergy, 39
anesthetics, iatrogenic effects, 138
ankyloblepharon, 74, 81, 90
ankylosing spondylarthritis, 145
antazoline, 60
anterior ciliary arteries, 22
anterior ciliary nerves, 23
antibiotics, 66, 106–107, 112, 113, 114, 130, 166
  iatrogenic effects, 136, 139
antibodies
  against mucins, 13–14
  in tear film, 8
  monoclonal, 38, 63, 128
  see also immunoglobulins
antibody-dependent cytotoxicity, 40
antigen presentation, 39
antigen-presenting cells (APCs), 28, 31, 39
  lymphocyte interactions, 33
antiglaucoma drugs, iatrogenic effects, 134, 137, 139–140
antihistamines, 60, 64, 65, 66
antiviral drugs, 114, 116, 117, 166
  iatrogenic effects, 136, 137, 139
apoptosis
  in conjunctiva, 45–46
    ocular surface disorders and, 45–46
  in dry eye syndromes and, 45, 157
  leukocytes, 28
arachidonic acid, 61
arteries, 22
arthralgia, 156
aspirin, 62, 65
astemizole, 60
astigmatism, 116
atopic dermatitis, 55, 56, 66
atopic keratoconjunctivitis, 42, 53, 55–56, 106
  clinical features, 56
  differential diagnosis, 56
  epidemiology, 55
  pathogenesis, 56
  therapy, 65–66
autoimmune bullous dermatosis (AIBD), 79–83
autoimmune fibrosing conjunctivitis, 73–86
  causes, 79–84
  clinical aspects, 73–75
  epidemiology, 73
  laboratory investigations, 75–79
    circulating antibodies, 78–79
    direct immunolabeling, 76–77
    pathology, 75–76
  pathogenesis, 73
  therapy, 84–86
    drug therapy, 84–86
    principles, 84
    surgical therapy, 86
autoimmunity, 28, 73
azathioprine, 84, 91, 171
azithromycin, 130

B

B cells, 28, 31, 32
  APC interactions, 33
  deficiencies, 155
bacterial conjunctivitis, 111–113, 114
  acute, 112–113
  superacute, 112
  see also specific types
basal cells, 4, 5, 18
basement membrane zone (BMZ), 5, 18, 76, 77, 146
  autoimmune diseases of, 79–82
benzalkonium, 106, 140–141, 158–159
biopsy, conjunctival, 42, 76, 137, 156
blepharitis, 65, 99, 100, 101, 102, 103, 154, 155, 158, 159
blood protein profile, 43
blood vessels, 22
Borrelia burgdorferi, 152
brucellosis, 151–152, 156
bulbar conjunctiva, 4
  conjunctival epithelium, 4
bullous pemphigoid *see* pemphigoid
bullous systemic lupus erythematosus, 82

C

cadherins, 18–20
Candida, 155
  conjunctivitis, 114
capillaries, 22
caruncle, 4, 11
cat-scratch disease, 113, 156
cataract, 54, 56
  surgical therapy, 86
ceftriaxone, 112, 114
cell–cell adhesion, 16
cellular immunity, 39–40
cephalosporins, 112, 114
cetirizine, 60
chalazia, 103
chickenpox, 117
chlamydiae, 55, 122–131
  bacteriology, 123
  Chlamydia pecorum, 123
  Chlamydia pneumoniae, 123, 127, 130
  Chlamydia psittaci, 123, 127, 130
  Chlamydia trachomatis, 112, 114, 123, 124–127, 145
    adult inclusion conjunctivitis, 125–126
    lymphogranuloma venereum, 127, 130
    neonatal conjunctivitis, 113, 114, 126
    Reiter's syndrome, 126–127, 130
    therapy, 114, 130
    see also trachoma
  immunity, 124
  laboratory investigations, 42, 127–129
    cell culture, 128
    complement fixation, 129
    direct immunofluorescence, 128–129
    guidelines, 129
    hybridization probes, 129
    immunoenzymatic techniques (ELISA), 129
    microimmunofluorescence, 129
    polymerase chain reaction, 129
  life cycle, 123–124
    elementary body, 123–124
    intermediate body, 124
    reticulate body, 123, 124
  nomenclature, 123
  therapy, 130
cholesterol esters, 101, 102
chorion, 5, 20–22
  collagens, 21
  elastic fibers, 21
  epithelial adhesion to, 18
  fibroblasts, 20–21
  ground substance, 23
  immunocompetent cells and cytokines, 23
chronic papillary conjunctivitis, 115
cicatricial pemphigoid *see* pemphigoid
cidofovir, 115
ciprofloxacin, 139
circulating antibody detection, 43, 79–79, 129
class II antigen restriction, 33
cockroach allergy, 59
Cogan's syndrome, 154, 156
colchicine, 85
collagens, 18, 21

complement fixation, 129
complement system, 38
congestion, 27
conjunctiva
  apoptosis in, 45–46
    dry eye syndromes and, 45
    ocular surface disorders and, 45–46
  defense mechanisms, 41–49
    mast cells, 48
    stroma, 47–48
  iatrogenic disorders, 136
conjunctiva-associated lymphoid tissue (CALT), 33, 48
conjunctival epithelium, 4–16, 47
  adhesion mechanisms, 16–20
    mechanical system, 16–18
    molecular interactions, 18–20
  basal cells, 4, 5, 18
  epithelial cell turnover, 45
  intermediate cells, 4, 5
  superficial cells, 4, 6–16
conjunctival glands, 4
conjunctivitis *see specific types*
contact conjunctivitis, 58
contact hypersensitivity, 40–41
contact lenses, 56–57, 66, 165, 166
  care of, 66
cornea
  fibrosing conjunctivitis and, 74, 90
  iatrogenic disorders, 137
  immune defenses, 48–49
  ocular rosacea and, 103–104
  surgical treatment of complications, 65, 66
  see also atopic keratoconjunctivitis; vernal conjunctivitis
corneal ectasia, 54
corticosteroids, 61, 64–65, 66, 83, 84, 85, 86, 90–91, 106, 116, 159, 166, 171
  iatrogenic effects, 136, 139
Corynebacterium, 41, 102, 110
  C. diphtheriae conjunctivitis, 112, 170
Coxsackie virus A24, 118–119
Crohn's disease, 151, 154, 156
cromoglycate *see* sodium cromoglycate
cryotherapy, 65
cyclooxygenase inhibitors, 61
cyclophosphamide, 84, 90, 91
cycloplegic agents, iatrogenic effects, 138
cyclosporine, 62–63, 65, 66, 83, 84, 85, 90, 159–160, 170, 171
cytokeratins, 7
cytokines, 22, 28, 32, 34–39, 157
  apoptosis and, 45
  conjunctival epithelium, 47
  in delayed-type hypersensitivity, 41
cytomegalovirus, 119
cytotoxic cells, 39–40

D

dacryoadenitis, 156
dapsone, 84, 85
Demodex follicularum, 100, 102
dendritic cells, 28–31
  cornea, 49
dermatitis herpetiformis, 73, 82, 85
dermatomyositis, 153
desmosomes, 5, 16, 20
dexamethasone, 61, 65, 130
diclofenac, 64
disodium cromoglycate *see* sodium cromoglycate
doxycycline, 106, 130
dry eye syndromes, 74, 90, 151, 154, 156, 157–160
  allergy-associated, 158
  conjunctival apoptosis and, 45
  infection-associated, 158
  laboratory investigation, 42, 59
  ocular rosacea and, 101, 102, 103
  ocular surface in, 149
  pathogenesis, 157
  tear deficiency-induced, 106
  therapy, 159–160
    androgens, 160
    antiinflammatory drugs, 159–160
    immunosuppressive drugs, 159–160
    tailored therapy, 159
  toxic, 158–159
see also Sjögren's syndrome

E

eczema, 136
edema, 27
elastic fibers, 21
elastin, 21
emedastine, 60
endothelial leukocyte adhesion molecule-1 (ELAM-1), 35
enterovirus 70, 118–119
eosinophil-derived neurotoxin (EDN), 43, 55
eosinophilic cationic protein (ECP), 55, 81
eosinophilic major basic protein (EMBP), 55, 56, 81
eosinophilio, 32, 35, 43
  polymorphonuclear, 35, 48, 170
  vernal keratoconjunctivitis, 55
epidemic keratoconjunctivitis, 115
epidermolysis bullosa acquisita, 73, 78, 82
  conjunctival biopsy, 42
epiligrin, 81
epinephrine, topical, 101
episcleritis, 104, 145, 150, 151
epithelium *see* conjunctival epithelium
Epstein–Barr virus, 158
  conjunctivitis, 116–117
erythema multiforme, 87
  see also Stevens–Johnson syndrome
erythromycin, 85, 106, 112, 114, 130
exophthalmia, 150
eyelids, iatrogenic disorders, 136

F

facial nerve, 23
fever, 156
fibrillin, 21
fibroblasts, 20–21
fibrosing conjunctivitis *see* autoimmune fibrosing conjunctivitis; nonautoimmune fibrosing conjunctivitis
fibrosis, 72, 103, 139–140, 150
  clinical aspects, 73–75
FK506 (Tacrolimus), 63, 91
fluorometholone, 61, 64
fluoroquinolones, 113
5-fluorouracil, 86
flurbiprofen, 61–62, 64
follicles, 111, 126
fornix, 3–4, 6
  conjunctival epithelium, 4
  foreshortening, 74, 75, 81, 90, 103
Francisella tularensis, 152
free radicals, 39
frontal nerve, 23
fusidic acid, 106

G

gamma interferon, 33, 36, 41, 47
gap junctions, 16
genital chlamydiosis, 125–126
gentamycin, 139
giant cell arteritis, 150
giant papillary conjunctivitis (GPC), 48, 53, 54, 56–58
  clinical features, 57
  differential diagnosis, 57
  epidemiology, 56–57
  pathogenesis, 57–58
  therapy, 66
glaucoma, 74, 86
  antiglaucoma drug iatrogenic effects, 134, 137, 139–140
goblet cells, 11, 12, 14, 47, 149
gonococcal conjunctivitis, 112
  neonatal, 113, 114
  therapy, 114
gout, 154
graft-versus-host disease, 151, 156
granulocyte colony-stimulating factor (G-CSF), 36
granulocyte macrophage-colony stimulating factor (GM-CSF), 28, 36
granulomatous inflammation, 28, 156
Grave's disease, 150
ground substance, chorion, 22

H

Haemophilus influenzae, 111, 112, 155
  conjunctivitis, 112, 114
haptens, 39, 40
hay fever conjunctivitis, 42, 53
  therapy, 63–64
Helicobacter pylori, 100
hemidesmosomes, 5, 18
hemochromatosis, 151
hemorrhagic conjunctivitis, 118–119
Henle's glands, 4
heparin, 171
hepatitis, 151, 156
hepatitis C virus, 158
herpes gestationis, 82
herpes virus, 55, 56
  herpes simplex, 87, 114, 116
  herpes zoster, 117
  laboratory investigations, 42
herpetic conjunctivitis, 114, 116
  clinical aspects, 116
  epidemiology, 116
  laboratory investigations, 116
  therapy, 114, 116
histamine, 34, 35
  receptors, 60
Hodgkin's disease, 156
human leukocyte antigens (HLA), 41, 47, 59
  HLA-B27-associated reactive arthritis, 145
human T cell leukemia virus type 1 (HTLV-1), 158
humoral response, 39
hyaluronidase, 171
hybridization probes, 129
hyperemia, 74, 111
hypersensitivity, 40–41
  iatrogenic disorders, 135, 136, 138
  type I, 31, 40, 53, 55, 135
  type II (antibody-dependent cytotoxicity), 40
  type III, 40
  type IV (delayed type), 31, 40–41, 55, 102, 135
hyperthyroidism, 150, 165
hyposensitization, 63, 65
hypothyroidism, 150–151

I

iatrogenic disorders, 134–141, 158–159
  allergic mechanisms, 135
  clinical aspects, 136–137
    conjunctiva, 136
    cornea, 137

eyelids, 136
presumed drug-induced cicatricial pemphigoid, 137
iatrogenic drugs, 138–141
antibiotics, 139
antiglaucoma drugs, 139–140
antiinflammatory drugs, 139
antivirals, 139
cycloplegic agents, 138
mydriatic agents, 138
preservatives, 140–141
topical anesthetics, 138
immunological mechanisms, 135
indirect mechanisms, 136
irritants, 135
laboratory investigations, 137–138
conjunctival allergen challenge, 138
conjunctival biopsy, 137
conjunctival scraping/smears, 137
IgE assay in tears, 137–138
impression cytology, 137
skin tests, 138
toxic effects, 135
immune memory, 28, 39
immunoelectron microscopy, 77, 79
immunoenzymatic techniques (ELISA), 77, 129
immunofluorescence
direct, 76–77, 128–129
indirect, 78
microimmunofluorescence, 129
immunoglobulins, 32–33, 36–38, 40, 57
IgE assay in tears, 42–43, 58, 59, 137–138
immunoglobulin superfamily, 18, 32
tear film, 41
see also antibodies
immunoprecipitation, 78–79
immunosuppressive chemotherapy, 151
immunotherapy, 63, 64, 84, 85
impression cytology, 42, 44, 58–59, 137
inclusion conjunctivitis, 122, 123
adult, 125–126
neonatal, 126
therapy, 130
see also chlamydiae
indomethacin, 65
infectious mononucleosis, 116, 117
inflammation, 27–28, 111, 140
antigen presentation, 39
cellular responses, 39–40
humoral responses, 39
local strategies, 41–49
conjunctiva, 41–49
cornea, 48–49
tear film, 41
main actors of, 28–35
dendritic cells, 28–31
lymphocytes, 31–33
macrophages, 31
mast cells, 33–35
polymorphonuclear eosinophils, 35
weapons of, 36–40
complement system, 38
cytokines, 36
free radicals, 39
immunoglobulins, 36–38
see also hypersensitivity
integrins, 18, 28, 32, 33, 35, 47
intercellular adhesion molecule (ICAM-1), 27, 28, 35, 41, 47, 49
interleukins, 32–33, 36, 47, 157
interleukin 2 receptor assay, 59
intermediate cells, 4, 5
iritis, 145
irritants, 135
isotretinoin, 101

J

junctional complexes, 16

K

Kaposi's sarcoma, 153
Kawasaki disease, 155, 156
keratectomy, 65, 86, 116
keratitis, 103–104, 115, 116, 117, 119, 127, 146, 148, 150, 151, 153, 154, 165
iatrogenic, 138, 139
keratoconjunctivitis *see specific types*
keratoconjunctivitis sicca, 145, 146, 150, 151, 154, 165
keratoconus, 54, 56
keratopathy, 137, 138, 153
keratoplasty, 66, 86, 91
keratoprosthesis, 86
ketorolac, 60, 61, 64
ketotifen, 60–61
kidney disorders, 155
Krause's glands, 4, 8

L

laboratory investigations, 42–43
blood protein profile, 43
circulating antibodies, 43
conjunctival biopsy, 42
conjunctival impression cytology, 42, 44
IgE assay in tears, 42–43
see also specific conditions
lacrimal glands, 8, 48, 159–160
lacrimal nerve, 23
lactoferrin, 8, 9, 41
lamina densa, 18
lamina lucida, 18
lamina propria, 20
laminins, 18
Langerhans cells, 4, 28–31, 47
cornea, 49
lectins, 12–13
leptospirosis, 152
leukocyte-function associated antigen (LFA), 27, 28, 41, 47
leukocytes, 27–28
leukotrienes, 61
inhibitors, 58, 63
levocabastine, 60, 64
lichen planus, 83
ligneous conjunctivitis, 168–171
limbal stem cell grafting, 91
limbus, 4, 6, 18
linear IgA dermatosis, 82
lipocalins, 8
lipooxygenase inhibitors, 63
lodoxamide, 60–61, 64
loratadine, 60
loteprednol etabonate, 61
Lyell syndrome, 72, 87
see also Stevens–Johnson syndrome
Lyme disease, 152
lymphatic vessels, 22
lymphocytes, 31–33, 48, 135
see also B cells; T cells
lymphogranuloma venereum, 127, 130
lymphoma, 156
lysozyme, 8, 9, 41

M

macrophage colony-stimulating factor (M-CSF), 36
macrophages, 31
major histocompatibility complex (MHC) antigens, 28, 47
Manz's glands, 4
mast cell stabilizers, 60–61, 64, 65, 66
mast cells, 32, 33–35, 48, 170
connective tissue mast cells (CTMC), 48
degranulation, 34, 48, 60, 61
mucosal mast cells (MMC), 48, 57
measles, 119
meibomian glands, 4, 8, 100
anatomy, 100
dysfunction, 98, 99, 102, 103, 158
pathogenesis, 101–102
obstruction, 101
secretion, 101
meibomitis, 56, 58, 99, 101, 102, 103, 106
complications, 103–104
melanocytes, 4
membranous conjunctivitis, 111, 169–170
meningococcal conjunctivitis, 111, 112
methotrexate, 84
methylcellulose, 166
metronidazole, 106
microimmunofluorescence, 129
microsporidiosis, 153
Mikulicz syndrome, 154
minocycline, 106
mipragoside, 65
mite allergy, 59
mitomycin C, 84, 86
mold allergy, 59
molluscum contagiosum conjunctivitis, 117–118
monoclonal antibodies, 38, 63, 128
mononuclear cells, 28
Moraxella, 112
M. lacunata conjunctivitis, 112
mucins, 11, 12–14, 41, 149
antibodies against, 13–14
genes, 14
lectin studies, 12–13
membrane mucins, 12
secreted mucins, 12
mucocutaneous junction, 3
mucolytic agents, 65, 66, 91
mucosa-associated lymphoid tissue (MALT), 7, 33, 48
mucous glands, 4
mucus, 8, 11, 12–14, 15, 41
composition, 12
functions, 14
laboratory investigations, 12–14
immunohistochemical methods, 13–14
lectins, 12–13
molecular biology, 14
periodic acid-Schiff stain–Alcian blue, 12
origin, 14
multiple endocrine neoplasms, 151
Mycobacterium tuberculosis, 152
mycophenolate mofetil, 84
Mycoplasma pneumoniae, 87
mydriatic agents, iatrogenic effects, 138

N

N-acetyl-aspartyl-glutamic acid (NAAGA), 60–61, 64
N-acetyl-cysteine, 91
naphazoline, 59
nasal nerve, 23
necrosis, 45, 111
nedocromil, 60, 61, 64, 66
Neisseria, 112, 113
N. gonorrhoeae, 111
N. meningitidis, 111
neonatal conjunctivitis, 113–114
causes, 114
epidemiology, 113
inclusion conjunctivitis, 126–127, 130
laboratory investigations, 114
therapy, 114, 130
nerve supply, 23
neutrophils, polymorphonuclear, 48

nitric oxide (NO), 31
non-Hodgkin's lymphoma, 154
nonautoimmune fibrosing conjunctivitis, 87–91
  causes, 87
  clinical aspects, 88–90
    ocular complications, 89–90
    systemic disease, 88
  epidemiology, 87–88
  immunopathology, 88
  therapy, 90–91
  see also Stevens–Johnson syndrome
nonsteroidal antiinflammatory drugs (NSAIDS), 61–62, 64, 65, 66
  iatrogenic effects, 139
norfloxacin, 130

O

ocular rosacea, 98–107, 156, 158, 159
  classification, 102
  complications, 103–104
  differential diagnosis, 105
  epidemiology, 99
  eyelid–conjunctival complex, 103
  pathogenesis, 100, 101–102
  treatment, 106–107
    antibiotics, 106–107
    lid hygiene, 106
ofloxacin, 130
olopatadine, 60–61
opportunistic conjunctivitis, 114
orbital conjunctiva, 3
oxymetazoline, 59
oxytetracycline, 106

P

palpebral arteries, 22
palpebral conjunctiva, 3–4, 22, 106
palpebral veins, 22
papillae, 111
papillary conjunctivitis *see* chronic papillary conjunctivitis; giant papillary conjunctivitis
papillomavirus conjunctivitis, 118
parasympathetic innervation, 23
Parinaud's oculoglandular syndrome, 111, 113, 127, 152
parotiditis, 156
patch tests, 58
pathology, 75–76
pemirolast, 60–61
pemphigoid, 73
  bullous, 7, 18, 73, 78, 81–82, 83
    conjunctival biopsy, 42
    therapy, 85
  cicatricial, 40, 72, 73, 78, 80–81
    conjunctival biopsy, 42, 76
    presumed drug-induced, 83–84, 137
    pure ocular, 83
    therapy, 84–85
    see also autoimmune fibrosing conjunctivitis
pemphigus, 73, 82–83
  therapy, 86
penetrating keratoplasty, 66, 86, 91
penicillin, 112, 114
perennial allergic conjunctivitis, 53–54
  therapy, 63–64
perforin, 39
periodic acid-Schiff stain, 12, 76
peripheral ulcerative keratitis, 40, 42, 48
peroxidase, 77
phagocytosis, 31
pharyngeal conjunctival fever, 115, 153, 156
pheniramine, 60
phenylephrine, 59, 111
  iatrogenic effects, 138
pinguecula, 48
plasma cells, 32, 48
plica semilunaris, 4, 11
pneumococci, 110
  pneumococcal conjunctivitis, 112, 114
polyarteritis nodosa, 43, 48, 150, 156
  childhood, 155
polychlorinated biphenyl, 101
polycythemia, 154
polymerase chain reaction (PCR), 129
polymyositis, 153
polymyxin B-neomycin-gramicidine, 113
polymyxin B-trimethoprim, 113
polyvidone iodine, 114
porphyria, 154
poxvirus, 117
prednisone, 84, 85, 86
preservatives, iatrogenic effects, 140–141, 158
prick test, 58
primary biliary cirrhosis, 151, 156
programmed cell death *see* apoptosis
progressive systemic sclerosis, 146–147, 156
propamidine isethionate, 139
Propionibacterium acnes, 41, 102, 110
prostaglandins, 61
pruritis, 136
pseudomembranes, 111, 153
psittacosis, 123, 127
psoriasis, 154, 156
pterygoid, 48
pyrilamine, 60

Q

quinolones, 112

R

radioallergosorbent testing (RAST), 59
Raynaud's phenomenon, 146, 147, 151, 156
reactive arthritis, 145
Reiter's syndrome, 126–127, 130, 145, 156
relapsing polychondritis, 145, 156
Rendu–Osler–Weber syndrome, 155
retinal detachment, 56
rheumatoid arthritis, 48, 145–146
rhinoconjunctivitis, 63
rhinophyma, 98, 99
rifamycin, 112, 114
rimexolone, 61
rosacea *see* ocular rosacea
roxithromycin, 114
rubella, 119

S

sarcoidosis, 43, 111, 153–154, 156
sclera, 4
scleritis, 40, 42, 104, 145, 148, 150
selectins, 18, 27, 32
serous glands, 4
silver nitrate, 166
Sjögren's syndrome, 7, 43, 146, 147–148, 151, 156, 158
  apoptosis in, 45
skin tests, 58, 138
sodium cromoglycate, 60–61, 64, 65, 66, 166, 171
Staphylococcus, 65–66, 101, 102, 106, 159
  S. aureus, 56, 102, 110, 111, 112, 170
    neonatal conjunctivitis, 114
  S. epidermidis, 41, 102, 110, 112, 155
  staphylococcal conjunctivitis, 112, 113
steroids, 61, 66, 84, 85, 90
  iatrogenic effects, 139
  see also corticosteroids
Stevens–Johnson syndrome, 72, 87–88, 170
  classification, 87
  clinical aspects, 89
    ocular complications, 89–90
  epidemiology, 87–88
  immunopathology, 88
  pathogenesis, 87
streptococci, 110
  streptococcal conjunctivitis, 112
  Streptococcus hemolyticus, 170
  Streptococcus viridans, 114
subconjunctival hemorrhage, 111, 154
suborbital nerve, 23
substantia propria, 47, 48
sulfasalazine, 84
sulphapyridine, 84
superantigens, 39
superficial cells, 4, 6–16
  apical membrane, 6
  basal membrane, 6
  cell types, 6–16
    type I cells (goblet cells), 11
    type II cells, 11
    type III cells, 16
    type IV cells, 16
    type V cells, 16
  lateral membrane, 6
superior limbic keratoconjunctivitis (SLK), 164–166
  clinical aspects, 165
  epidemiology, 165
  pathogenesis, 165–166
  pathology, 165
  treatment, 166
surgical treatment, 65, 66
  autoimmune fibrosing conjunctivitis, 86
  ligneous conjunctivitis, 170
  nonautoimmune fibrosing conjunctivitis, 91
  palpebro-conjunctival scars, 66
  superior limbic keratoconjunctivitis, 166
  trachoma, 130
  vernal plaque, 65
swimming pool conjunctivitis, 125
symblephara, 74, 75, 81, 90, 103
sympathetic innervation, 23
synthetic human IgE pentapeptide (HEPP), 63
syphilis, 152, 156
systemic lupus erythematosus, 43, 146, 156

T

T cells, 28, 31, 32, 47, 170
  APC interactions, 33, 39
  helper T cells, 28, 32, 39, 135
  Th1/Th2 system, 32–33, 43, 135, 138
Tacrolimus, 63, 91
tarsus, 3, 6
  conjunctival epithelium, 4
tear film, 4, 8–9, 41, 101, 148
  aqueous layer, 8
  iatrogenic modifications, 136
  IgE assay, 42–43
  laboratory investigations, 9, 101
  lipid layer, 8
  mucus layer, 8
  role, 9, 41
  tear deficiency, 106, 148
  tear function index, 149
telangiectasia, 98, 99, 103, 147
  hereditary hemorrhagic, 155
Tenon's capsule, 4
terfenadine, 60, 64
tetracycline, 85, 106, 114, 127, 130, 159
tetrahydrozoline, 59
Thygeson keratitis, 115, 165
thymoindependent antigens, 39
tight junctions, 16, 20
tolerance, 45–46, 63
tonofilaments, 5, 18

toxic conjunctivitis, 114
toxic epidermal necrolysis, 72, 87
  clinical aspects, 89
    ocular complications, 89–90
  epidemiology, 87
  see also Stevens–Johnson syndrome
trachoma, 72, 87, 122, 123, 124–125
  clinical aspects, 124–125
    cicatricial trachoma, 125
    florid trachoma, 124–125
    precicatricial trachoma, 125
    trachoma incipiens, 124
  complications, 125
  diagnosis, 127
  epidemiology, 124
  therapy, 130
  see also chlamydiae
Treponema pallidum, 152
trifluridine, 115
trigeminal nerve, 23
tryptase assay in tears, 59
tuberculosis, 152, 156
tularemia, 152, 156
tumor necrosis factor alpha (TNF-α), 28, 31, 36

U

Ureaplasma urealytica, 145
urogenital chlamydiosis, 125–126
urticaria, 136
uveitis, 116, 153

V

valaciclovir, 117
varicella-zoster virus conjunctivitis, 117
vascular cell adhesion molecule (VCAM-1), 27
vasoconstrictors, 59–60, 138
veins, 22
vernal conjunctivitis, 33, 42, 48, 53, 54–55, 127
  clinical features, 54
  differential diagnosis, 54–55, 57
  epidemiology, 54
  pathogenesis, 55
  therapy, 64–65
very late activation antigen (VLA-1), 27–28
viral conjunctivitis, 111, 114, 115–119
  see also specific types
vitamin A, 166
  deficiency, 150, 151
vitamin B deficiency, 150

W

weed allergy, 59
Wegener's granulomatosis, 148–150, 156
Western immunoblotting, 78–79
Whipple's disease, 151, 156
Willis ophthalmic branch, trigeminal nerve, 23
Wolfring's glands, 4, 8

X

xerophthalmia, 148, 151, 156
xerostomia, 146, 147, 148

Z

Zeiss glands, 4
zonula occludens, 16